You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company recently received FDA Emergency Use Authorization for its SARS-CoV-2 PCR test while its data-driven COVID-19 research initiative is moving along.
The company's host-response diagnostics read the immune system using a machine learning algorithm and multiple mRNA biomarkers.
The company's mobile app provides automated COVID-19 screening and directs potential patients to testing locations for confirmatory testing.
The company is using newly raised funds to support a disseminated trial model, which it said will help it keep its plans to finish the study by the end of 2021.
BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.
The Oslo-based company plans to develop a test that can identify high-risk individuals based on an epigenetic signature.
The firms supporting the new lab include Thermo Fisher Scientific, Canon Medical, and Siemens Healthineers, all of which will contribute their know-how and technologies to the effort.
The firm said it will use the new capital to further develop cancer pathology workflows and create custom diagnostic and clinical trial solutions.
The researchers are developing an automated machine-learning approach to analyze the expression of protein markers associated with cervical cancer.
The technology from Scanwell is also being used for its at-home SARS-CoV-2 antibody test, which is under development and awaiting Emergency Use Authorization.